EHC - European Haemophilia Consortium/LinkedIn
Oct 1, 2025, 16:30
Emicizumab Approvals in Europe: European Haemophilia Consortium Shares Key Updates
European Haemophilia Consortium (EHC) posted on LinkedIn:
”Indications of non-factor treatments for haemophilia A are evolving.
In Europe, Emicizumab is approved for routine prophylaxis for moderate haemophilia A with severe bleeding, for severe haemophilia A and for haemophilia A with factor VIII inhibitors.
It is always a good idea to consult local regulatory authorities for the precise current approved use in your area.
Learn more in the EHCucate topic Emicizumab Basics, available on the EHC Academy.”
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25